Interleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis
暂无分享,去创建一个
S. Loosen | F. Tacke | C. Trautwein | A. Wree | A. Birmingham | A. Feldstein | C. Roderburg | K. Fisch | J. Hundertmark | J. Schilling | H. Hoffman | B. Kaufmann | M. Demir | Jana Knorr | M. Kohlhepp | M. Inzaugarat | T. Holtmann | Lukas Geisler | Daisy Chilin-Fuentes | Laela M Boosheri | Daisy R. Chilin-Fuentes | Daisy Chilin-Fuentes
[1] S. Ogawa,et al. A Possible Association Between a Nucleotide‐Binding Domain LRR‐Containing Protein Family PYD‐Containing Protein 1 Mutation and an Autoinflammatory Disease Involving Liver Cirrhosis , 2021, Hepatology.
[2] H. Zischka,et al. IL-18 But Not IL-1 Signaling Is Pivotal for the Initiation of Liver Injury in Murine Non-Alcoholic Fatty Liver Disease , 2020, International journal of molecular sciences.
[3] F. Jamali,et al. Single dose pharmacokinetics and bioavailability of glucosamine in the rat. , 2002, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.
[4] D. Schuppan,et al. Comparison of murine steatohepatitis models identifies a dietary intervention with robust fibrosis, ductular reaction, and rapid progression to cirrhosis and cancer , 2019, American journal of physiology. Gastrointestinal and liver physiology.
[5] F. Tacke,et al. Single Cell RNA Sequencing Identifies Subsets of Hepatic Stellate Cells and Myofibroblasts in Liver Fibrosis , 2019, Cells.
[6] F. Negro,et al. Interleukin-1 Receptor Antagonist Modulates Liver Inflammation and Fibrosis in Mice in a Model-Dependent Manner , 2019, International journal of molecular sciences.
[7] R. Schwabe,et al. NLR Family Pyrin Domain‐Containing 3 Inflammasome Activation in Hepatic Stellate Cells Induces Liver Fibrosis in Mice , 2019, Hepatology.
[8] Lin Wang,et al. Neutralization of IL-18 by IL-18 binding protein ameliorates bleomycin-induced pulmonary fibrosis via inhibition of epithelial-mesenchymal transition. , 2019, Biochemical and biophysical research communications.
[9] Han-bing Wang,et al. Inhibition of IL-18 reduces renal fibrosis after ischemia-reperfusion. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[10] G. Kaplanski. Interleukin‐18: Biological properties and role in disease pathogenesis , 2017, Immunological reviews.
[11] F. Spertini,et al. Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still’s disease , 2017, Annals of the rheumatic diseases.
[12] W. Gao,et al. IL-18 cleavage triggers cardiac inflammation and fibrosis upon &bgr;-adrenergic insult , 2018, European heart journal.
[13] A. Wree,et al. NLRP3 inflammasome driven liver injury and fibrosis: Roles of IL‐17 and TNF in mice , 2018, Hepatology.
[14] S. Friedman,et al. Mechanisms of hepatic stellate cell activation , 2017, Nature Reviews Gastroenterology &Hepatology.
[15] K. Schroder,et al. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. , 2017, Journal of hepatology.
[16] A. Gerbes,et al. Role of interleukin-1 and its antagonism of hepatic stellate cell proliferation and liver fibrosis in the Abcb4(-/-) mouse model. , 2016, World journal of hepatology.
[17] Haitao Guo,et al. Inflammasomes: mechanism of action, role in disease, and therapeutics , 2015, Nature Medicine.
[18] A. Regev,et al. Spatial reconstruction of single-cell gene expression data , 2015 .
[19] M. Shirakawa,et al. The structural basis for receptor recognition of human interleukin-18 , 2014, Nature Communications.
[20] A. Wree,et al. NLRP3 inflammasome activation is required for fibrosis development in NAFLD , 2014, Journal of Molecular Medicine.
[21] A. Wree,et al. NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice , 2014, Hepatology.
[22] James L. Mueller,et al. Divergence of IL-1, IL-18, and cell death in NLRP3 inflammasomopathies. , 2013, The Journal of clinical investigation.
[23] D. Stainier,et al. Hepatic stellate cells in liver development, regeneration, and cancer. , 2013, The Journal of clinical investigation.
[24] C. Tanaka,et al. An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis , 2013, International journal of experimental pathology.
[25] M. Idzko,et al. IL‐18 associates to microvesicles shed from human macrophages by a LPS/TLR‐4 independent mechanism in response to P2X receptor stimulation , 2012, European journal of immunology.
[26] R. Schwabe,et al. Deactivation of hepatic stellate cells during liver fibrosis resolution in mice. , 2012, Gastroenterology.
[27] Christopher K. Glass,et al. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis , 2012, Proceedings of the National Academy of Sciences.
[28] A. Feldstein,et al. Caspase 1-mediated regulation of fibrogenesis in diet-induced steatohepatitis , 2011, Laboratory Investigation.
[29] K. Meldrum,et al. IL-18 neutralization ameliorates obstruction-induced epithelial-mesenchymal transition and renal fibrosis. , 2009, Kidney international.
[30] D. Kastner,et al. Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity. , 2009, Immunity.
[31] K. Wallace,et al. Interleukin-1 participates in the progression from liver injury to fibrosis. , 2009, American journal of physiology. Gastrointestinal and liver physiology.
[32] H. Tilg,et al. Elevated systemic levels of free interleukin-18 (IL-18) in patients with Crohn's disease. , 2005, European cytokine network.
[33] M. Miyazaki,et al. Interleukin 18 causes hepatic ischemia/reperfusion injury by suppressing anti‐inflammatory cytokine expression in mice , 2004, Hepatology.
[34] H. Tilg,et al. Plasma Levels of Interleukin-18 and Interleukin-18 Binding Protein Are Elevated in Patients with Chronic Liver Disease , 2002, Journal of Clinical Immunology.
[35] Masafumi Koga,et al. Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. , 2003, Metabolism: clinical and experimental.
[36] Tom Boone,et al. IL-18-Binding Protein Protects Against Lipopolysaccharide- Induced Lethality and Prevents the Development of Fas/Fas Ligand-Mediated Models of Liver Disease in Mice , 2001, The Journal of Immunology.
[37] J. Losy,et al. IL‐18 in patients with multiple sclerosis , 2001, Acta neurologica Scandinavica.
[38] G. Fantuzzi,et al. A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18. , 2001, Cytokine.
[39] S. Akira,et al. Lipopolysaccharide-Induced IL-18 Secretion from Murine Kupffer Cells Independently of Myeloid Differentiation Factor 88 That Is Critically Involved in Induction of Production of IL-12 and IL-1β1 , 2001, The Journal of Immunology.
[40] V. Mehta,et al. ATP-stimulated Release of Interleukin (IL)-1β and IL-18 Requires Priming by Lipopolysaccharide and Is Independent of Caspase-1 Cleavage* , 2001, The Journal of Biological Chemistry.
[41] T. Tanimoto,et al. Interferon-gamma-inducing activity of interleukin-18 in the joint with rheumatoid arthritis. , 2001, Arthritis and rheumatism.
[42] T. Tanimoto,et al. Serum interferon‐gamma‐inducing factor/IL‐18 levels in primary biliary cirrhosis , 2000, Clinical and experimental immunology.
[43] T. Tanimoto,et al. Elevation of serum interleukin-18 levels and activation of Kupffer cells in biliary atresia. , 2000, Journal of pediatric surgery.
[44] L. Joosten,et al. Neutralization of IL-18 Reduces Neutrophil Tissue Accumulation and Protects Mice Against Lethal Escherichia coli and Salmonella typhimurium Endotoxemia1 , 2000, The Journal of Immunology.
[45] M Eisenstein,et al. Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[46] J. Wilcox,et al. Human keratinocytes constitutively express interleukin-18 and secrete biologically active interleukin-18 after treatment with pro-inflammatory mediators and dinitrochlorobenzene. , 1999, The Journal of investigative dermatology.
[47] G. Fantuzzi,et al. Gene expression, synthesis, and secretion of interleukin 18 and interleukin 1beta are differentially regulated in human blood mononuclear cells and mouse spleen cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[48] C. Moskaluk,et al. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. , 1998, Journal of immunology.
[49] T. Born,et al. Cloning of a Novel Receptor Subunit, AcPL, Required for Interleukin-18 Signaling* , 1998, The Journal of Biological Chemistry.
[50] H. Okamura,et al. Propionibacterium acnes treatment diminishes CD4+ NK1.1+ T cells but induces type I T cells in the liver by induction of IL-12 and IL-18 production from Kupffer cells. , 1997, Journal of immunology.
[51] R. Kamen,et al. Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production. , 1997, Nature.
[52] H. Okamura,et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. , 1995, Nature.